AccentHealth adds 1,000 waiting room TVs

Share this article:
AccentHealth buys Havas point-of-care unit, doubles footprint
AccentHealth buys Havas point-of-care unit, doubles footprint

Having doubled its waiting room wallboards franchise by buying Havas's point of care unit, AccentHealth is moving to boost the digital side of its business with its acquisition of MediVista Media's Everwell TV network.

It's a smaller buy, putting AccentHealth video and interactive content in an additional 1,000 waiting rooms and boosting the company's TV network to 13,500 offices. AccentHealth has Health Panels and TV screens in 30,000 offices nationwide. The company is also looking to broaden its media mix throughout its network to include TV, print, literature distribution and some new interactive products.

“We have offices where we have both formats,” said EVP business and product development John Curbishley. “We think they're complimentary. What we're trying to do is allow the client to be able to brand the office with a range of touchpoints in print and digital.”

Clients, said Curbishley, are “really focused on the kind of scale we can provide. They're looking for overall reach, whether print or digital, but also targeted reach into particular conditions, geographies and demographics, and this is a nice deal for us because it extends our reach in all those areas.”

MediVista's Everwell unit will continue to produce health programming, but without its own waiting room network.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...